Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with
68 Ga-labeled compounds has rapidly become adopted as part of routine clinical care in …

The continuing adoption of prostate specific membrane antigen (PSMA)-targeted PET for
prostate cancer molecular imaging requires imagers and clinicians alike to be aware of the …

Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …

Chimeric antigen receptor (CAR) T cell therapy for hematologic malignancies is fraught with
several unknowns, including number of functional T cells that engage target tumor, durability …

Abstract Prostate-specific Membrane Antigen Reporting and Data System (PSMA-RADS)
was introduced for standardized reporting, and PSMA-RADS version 1.0 allows …

Background Accurate classification of sites of interest on prostate-specific membrane
antigen (PSMA) positron emission tomography (PET) images is an important diagnostic …

Standardized staging and quantitative reporting are necessary to demonstrate the
association of 18F-DCFPyL PET/CT imaging with clinical outcome. This work introduces an …

In this article, we provide an overview of established and emerging conventional nuclear
medicine and PET imaging biomarkers, as the diagnostic nuclear medicine portfolio is …

Abstract Purpose The performance of 68 Ga-PSMA PET/CT-MR has been evaluated in
prostate cancer (PCa), showing significant results. However, even a technically accurate …

More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept
of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors …